Form 8-K - Current report:
SEC Accession No. 0000950170-25-025596
Filing Date
2025-02-24
Accepted
2025-02-24 16:05:08
Documents
11
Period of Report
2025-02-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K atos-20250221.htm   iXBRL 8-K 44615
  Complete submission text file 0000950170-25-025596.txt   163593

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20250221.xsd EX-101.SCH 28515
13 EXTRACTED XBRL INSTANCE DOCUMENT atos-20250221_htm.xml XML 4682
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 25656940
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)